I have taken a position here over the last 2 weeks and topping up last week, after selling half of another very promising neurodegenerative disease stock on release great topline phase 2 data.
Some great posts here and thank you for providing valuable insight to what is a promising unique mechanism of action in a few mammoth addressable markets. Ontop of AD and Depression/Anxiety I also feel if Xanamen is proven to be safe it could have merit eventually as an expensive supplement for longevity. Steven Gourlay eluded to a possible opportunity in the longevity market in the PSR life sciences conference webinar.
If we see some endpoints met in the prelim data it could be a quick ride to unicorn town and an amazing result for patients.
GLA
ACW Price at posting:
3.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)